Effect of Topotecan on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer

By Nielsen H.A.   Nielsen D.   Engelholm S.A.  

Gynecologic Oncology, Vol. 77, Iss. 3, 2000-06 ,pp. : 383-388

Elsevier

Access to resources Recommend Favorite

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

By Gore M.   Oza A.   Rustin G.   Malfetano J.   Calvert H.   Clarke-Pearson D.   Carmichael J.   Ross G.   Beckman R.A.   Fields S.Z.  

European Journal of Cancer, Vol. 38, Iss. 1, 2002-01 ,pp. : 57-63

Elsevier

Access to resources Recommend Favorite

Plasma and Salivary Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer Receiving 5-FU Bolus Plus Continuous Infusion with High-dose Folinic Acid

By Joulia J.M.   Pinguet F.   Ychou M.   Duffour J.   Astre C.   Bressolle F.  

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 296-301

Elsevier

Access to resources Recommend Favorite

Biomarker Conservation in Primary and Metastatic Epithelial Ovarian Cancer

By Tewari K.S.   Kyshtoobayeva A.S.   Mehta R.S.   Yu I.-R.   Burger R.A.   DiSaia P.J.   Fruehauf J.P.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 130-136

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite